United Therapeutics gets NA rights to Samumed's IPF candidate; deal terminated
Samumed LLC licensed United Therapeutics Corp. exclusive rights to develop and commercialize its SM04646 in the US and Canada.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.